VETERINARY MEDICINE

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

S4 **NUMELVI®** 4,8 mg tablets for dogs
S4 **NUMELVI®** 7,2 mg tablets for dogs
S4 **NUMELVI®** 21,6 mg tablets for dogs
S4 **NUMELVI®** 31,6 mg tablets for dogs

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each tablet contains:

Atinvicitinib	4,8 mg
or	
Atinvicitinib	7,2 mg
or	
Atinvicitinib	21,6 mg
or	
Atinvicitinib	31,6 mg

Excipients:

Cellulose, microcrystalline
Hydroxypropylcellulose
Lactose monohydrate
Magnesium stearate
Silica, colloidal anhydrous
Sodium starch glycolate (type A)
Tocofersolan

White to off-white, oblong shaped tablets with one marked score-line on each side and marked with "S", "M","L" or “XL” on each half of the top side. The letters "S", "M", "L" and “XL” refer to the different strengths of tablets.
Strength “S” is on the 4,8 mg tablets: Approximate length 9,7 mm, width 4,9 mm, and thickness 3,9 mm.
Strength “M” is on the 7,2 mg tablets: Approximate length 11,0 mm, width 5,5 mm, and thickness 4,3 mm.
Strength “L” is on the 21,6 mg tablets: Approximate length 15,9 mm, width 7,9 mm, and thickness 6,2 mm.
Strength “XL” is on the 31,6 mg tablets: Approximate length 18,2 mm, width 9,2 mm, and thickness 6,9 mm.
The tablets can be divided into two equal halves.

3. CLINICAL INFORMATION

3.1 Target species

Dogs.

3.2 Indications for use for each target species

Numelvi® is indicated for the treatment of pruritus, inflammation and clinical manifestations associated with allergic dermatitis, including atopic dermatitis in dogs.

3.3 Contraindications

Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

3.4 Special warnings

- In the absence of available data, **Numelvi®** should not be used in dogs less than 6 months old.
- Treatment for non-atopy dermatitis needs to be evaluated for continued treatment after 30 days. Treatment must be combined with the removal of the inciting cause, such as bacterial, fungal or parasitic infections (e.g., fleas, *Demodex* mites), as well as any underlying causes (e.g., flea allergy, contact allergy, food allergy) of allergic and atopic dermatitis.

3.5 Special precautions for use

- Wash hands thoroughly with soap and water immediately after use of **Numelvi®**.
- Medicines should not be disposed of via wastewater or household waste. Disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements.
- KEEP OUT OF REACH AND SIGHT OF CHILDREN, UNINFORMED PERSONS AND ANIMALS.

3.6 Adverse events

Dogs:

Common (1 to 10 animals/100 animals treated):	Vomiting[1], diarrhoea[1], lethargy[1], decreased appetite[1]

[1]mild and self-resolving

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or SAHPRA via the national reporting system. See the package leaflet for respective contact details.

3.7 Use during pregnancy or lactation

The safety of **Numelvi®** has not been established during pregnancy and lactation or in breeding dogs. Therefore, the use in those dogs is not recommended.

3.8 Interaction with other medicinal products and other forms of interaction

None known. No drug interactions were observed in field studies where **Numelvi®** was administered concomitantly with other veterinary medicinal products such as antimicrobials (including topicals), ecto- and endoparasiticides (isoxazolines, milbemycins, avermectins, pyrethrins and pyrethroids), analgesics, anaesthetics, nutritional supplements, topical skin

and ear cleansers that did not contain glucocorticoids, as well as medicated shampoos. The risk of drug-drug interactions is very low due to limited effect of atinvicitinib on cytochrome P450.

There was no impact on immune response to vaccination. **Numelvi®** was well tolerated with no adverse clinical effects related to treatment when used concomitantly with vaccination. An adequate immune response (serology) to modified live Canine Adenovirus type-2 (CAV), modified live Canine Distemper Virus (CDV), modified live Canine Parvovirus (CPV), and inactivated Rabies Virus (RV) vaccination was achieved when 6-month-old vaccine naïve puppies were administered **Numelvi®** at 3,6 mg/kg atinvicitinib (3 times the maximum labelled dose) once daily for 84 days.

3.9 Administration routes and dosage

For oral use in dogs.

Numelvi® should be administered once daily, at or within 30 minutes of feeding, in accordance with the following dosing table (corresponding to a dose of 0,8 to 1,2 mg atinvicitinib/kg body weight within one weight band):

Strength and number of tablets to be administered				
Body weight of dog (kg)	**Numelvi® 4,8 mg**	**Numelvi® 7,2 mg**	**Numelvi® 21,6 mg**	**Numelvi® 31,6 mg**
2,0 - 2,9	1/2			
3,0 - 4,3		1/2		
4,4 - 6,0	1			
6,1 - 9,0		1		
9,1 - 13,5			1/2	
13,6 - 19,3				1/2
19,4 - 26,5			1	
26,6 - 39,5				1
39,6 - 54,0				1 1/2
54,1 - 79,0				2

The tablets are breakable along the score line.

For dogs above 79 kg body weight, use a combination of full or half tablets to achieve a target dose of 0,8 to 1,2 mg/kg body weight.

3.10 Symptoms of overdose

Numelvi® has a wide therapeutic window and was well tolerated when administered orally to healthy 6-month-old puppies treated with overdoses of up to 5 times the maximum recommended dose once daily over a period of 6 months.
In case of adverse effects following an overdose, the dog should be treated symptomatically.

3.11 Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance

Not applicable.

3.12 Withdrawal periods

Not applicable.

4. PHARMACOLOGICAL ACTION

PHARMACOLOGICAL CLASSIFICATION

C.13. Dermatological

Pharmacodynamics

Atinvicitinib is a selective Janus kinase (JAK) inhibitor, highly selective for JAK1. It inhibits the function of a variety of cytokines involved in itching and inflammation, as well as cytokines involved in allergy, that are dependent on JAK1 enzyme activity.
Atinvicitinib is at least 10 times more selective for JAK1 compared to the other JAK-family members (JAK2, JAK3, Tyrosine Kinase (TYK)2). Thus, it has very little to no effect on cytokines involved in haematopoiesis or host defense that are dependent on JAK2 or the other JAK family members.

Pharmacokinetics

Following oral administration, atinvicitinib was rapidly and well absorbed with an observed mean C_{max} of 190 ng/mℓ, which occurred at approximately 1 hour (T_{max}) post dosing. The absolute bioavailability of atinvicitinib after administration once daily for 4 days was approximately 65 %. Bioavailability was higher in fed dogs. Total body atinvicitinib clearance from plasma was 1 074 mℓ/h/kg body weight (17,9 mℓ/min/kg body weight), and the apparent volume of distribution at steady state was 1 651 mℓ/kg body weight. Following oral administration, the terminal half-life ($T_{1/2}$) was 2 hours.
Atinvicitinib has moderate protein binding with 82,3 % bound in fortified canine plasma at concentrations of 1 802 ng/mℓ (5 μM).
Atinvicitinib is metabolised in the dog to multiple metabolites. Overall clearance route is metabolism with excretion in the faeces, while renal elimination with excretion in urine is a minor route.

5. PHARMACEUTICAL PARTICULARS

5.1 Major incompatibilities

None known.

5.2 Shelf life

Shelf life of the veterinary medicinal product as packaged for sale: 36 months.
After opening, tablets can be stored for up to 60 days in the 30 count bottle and for up to 180 days in the 90 count bottle.

Remaining half tablets from blisters should be discarded after 9 days.

5.3 Special precautions for storage

Store below 30 ˚C.
Store in the original bottle and carton.
Any remaining half tablet(s) should be placed back into the opened blister or into the bottle.
Do not use **Numelvi®** after the expiry date which is stated on the blister or bottle.
The expiry date refers to the last day of that month.

5.4 Nature and composition of immediate packaging

Silver aluminium/PVC/transparent aclar blisters (each strip containing 30 tablets) or white to off-white colour HDPE plastic bottle with child resistant closure.
Pack sizes of 30 and 90 tablets.
Not all pack sizes may necessarily be marketed.

5.5 Special precautions for the disposal of unused veterinary medicinal products or waste materials derived from the use of such products

Medicines should be disposed of according to local requirements.

6. NAME OF THE MARKETING AUTHORISATION HOLDER

Intervet South Africa (Pty) Ltd.
20 Spartan Road, Spartan
1619, RSA
Tel: +27 (0) 11 923 9300
E-mail: msdahza@msd.com
www.msd-animal-health.co.za

MANUFACTURER

Intervet Ges.m.b.H
Siemensstrasse 107
1210 Vienna, Austria

7. MARKETING AUTHORISATION NUMBER(S)

NUMELVI® 4,8 mg tablets for dogs 25/13/01 (Act 101/1965)
NUMELVI® 7,2 mg tablets for dogs 25/13/02 (Act 101/1965)
NUMELVI® 21,6 mg tablets for dogs 25/13/03 (Act 101/1965)
NUMELVI® 31,6 mg tablets for dogs 25/13/04 (Act 101/1965)

8. DATE OF FIRST AUTHORISATION

31 March 2026

9. DATE OF THE LAST REVISION OF THE SUMMARY OF THE PRODUCT CHARACTERISTICS

31 March 2026

10. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCTS

C.13. Dermatological